SuperGen’s Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting

SuperGen’s Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting

Data Indicate That SuperGen’s Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation in Non-clinical Models

Data Indicate That SuperGen’s Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation in Non-clinical Models

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology’s 49th Annual Meeting

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology’s 49th Annual Meeting

Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting

Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting

Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging Agents

Data Show SuperGen’s Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging Agents